137 results on '"Gebo, Kelly A"'
Search Results
2. The association of a scholarly concentrations program with medical students' matched residencies.
- Author
-
Alkhatib, Hosam H., Beach, Mary Catherine, Gebo, Kelly A., Bass, Eric B., Park, Jenny R., Atkinson, Meredith A., Kudchadkar, Sapna R., and Sozio, Stephen M.
- Subjects
- *
MEDICAL students , *MEDICAL school curriculum , *RESIDENTS (Medicine) , *STUDENT publications , *STUDENT interests - Abstract
Purpose: Many medical school curricula include Scholarly Concentrations (SC) programs. While studies have examined how these programs affect students' future research involvement, the association of SC programs with students' specialty choices is uncertain. This study examines the SC program factors associated with congruence between the specialty focus of students' SC projects and the clinical specialty they matched into for residency. Methods: The authors conducted a retrospective cohort study of all students participating in the SC program at Johns Hopkins University School of Medicine for graduating classes 2013-2020. They used data from program questionnaires to categorize students' specialty interests (baseline) and SC program experiences (post-program). The authors categorized each student's project into specialties according to their faculty mentors' primary appointments, abstracted student publications from SCOPUS, and abstracted residency program rankings from Doximity Residency Navigator. The authors used multivariable logistic regression to calculate adjusted odds ratios (aOR) for specialty-congruent matching (same specialty as SC project) and for matching into a Doximity-ranked top 20 or top 10 program. Results: Overall, 35.3% of the 771 students matched into the same specialty as their SC projects. Increased odds of specialty-congruent matching occurred with 'definite' interest in the specialty at baseline [aOR (95% CI): 1.76 (0.98-3.15)] (P = 0.06) and with increasing publications with SC mentors [aOR (95% CI): 1.16 (1.03-1.30)] (P = 0.01). Congruence between SC specialty focus and matched specialty conferred no significant difference in odds of matching to a Doximity-ranked top 20 or top 10 program. Conclusions: Baseline certainty of specialty interest and research productivity were associated with specialty congruence. However, as completing an SC project in a given specialty was not associated with increased odds of matching into that specialty nor into a higher Doximity-ranked program, SC program directors should advise students to pursue SC projects in any topic of personal interest. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004–2014.
- Author
-
Raifman, Julia R., Gebo, Kelly A., Mathews, William Christopher, Korthuis, Philip Todd, Ghanem, Khalil G., Aberg, Judith A., Moore, Richard D., Nijhawan, Ank E., Monroe, Anne K., and Berry, Stephen A.
- Abstract
Objectives: Annual screening for gonorrhea [Neisseria gonorrhoeae (NG)] and chlamydia [Chlamydia trachomatis (CT)] is recommended for all sexually active persons living with HIV but is poorly implemented. Studies demonstrating no increases in NG and/or CT (NG/CT) case detection in clinics that successfully expanded NG/CT screening raise questions about this broad screening approach. We evaluated NG/CT case detection in the HIV Research Network during 2004–2014, a period of expanding testing. Methods: We analyzed linear time trends in annual testing (patients tested divided by all patients in care), test positivity (patients positive divided by all tested), and case detection (the number of patients with a positive result divided by all patients in care) using multivariate repeated measures logistic regression. We determined trends overall and stratified by men who have sex with men (MSM), men who have sex exclusively with women, and women. Results: Among 15,614 patients (50% MSM, 26% men who have sex exclusively with women, and 24% women), annual NG/CT testing increased from 22% in 2004 to 60% in 2014 [adjusted odds ratio (AOR) per year 1.22 (1.21–1.22)]. Despite the increase in testing, test positivity also increased [AOR per year 1.10 (1.07– 1.12)], and overall case detection increased from 0.8% in 2004 to 3.9% in 2014 [AOR per year 1.20 (1.17–1.22)]. Case detection was highest among MSM but increased over time among all 3 groups. Conclusions: NG/CT case detection increased as testing expanded in the population. This supports a broad approach to NG/CT screening among persons living with HIV to decrease transmission and complications of NG/CT and of HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Progress With the All of Us Research Program: Opening Access for Researchers.
- Author
-
Ramirez, Andrea H., Gebo, Kelly A., and Harris, Paul A.
- Subjects
- *
HUMAN genome , *DATABASES , *COHORT analysis , *MEDICAL research , *GENETICS - Abstract
This Viewpoint summarizes enrollment to date in the All of Us Research Program, a cohort study launched in 2018 designed to enroll ≥1 million participants, including those from historically underrepresented backgrounds, to diversify the human genome database and the infrastructure it is building to broadly share its data assets to improve and accelerate biomedical research. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.
- Author
-
Crowell, Trevor A., Gebo, Kelly A., Blankson, Joel N., Korthuis, P. Todd, Yehia, Baligh R., Rutstein, Richard M., Moore, Richard D., Sharp, Victoria, Nijhawan, Ank E., Mathews, W. Christopher, Hanau, Lawrence H., Corales, Roberto B., Beil, Robert, Somboonwit, Charurut, Edelstein, Howard, Allen, Sara L., and Berry, Stephen A.
- Subjects
- *
HIV infections , *HOSPITAL care , *ANTIRETROVIRAL agents , *INFLAMMATION , *PATHOLOGICAL psychology , *IMMUNE system - Abstract
Background. Elite controllers spontaneously suppress human immunodeficiency virus (HIV) viremia but also demonstrate chronic inflammation that may increase risk of comorbid conditions. We compared hospitalization rates and causes among elite controllers to those of immunologically intact persons with medically controlled HIV. Methods. For adults in care at 11 sites from 2005 to 2011, person-years with CD4 T-cell counts ⩾350 cells/mm2 were categorized as medical control, elite control, low viremia, or high viremia. All-cause and diagnostic categoryspecific hospitalization rates were compared between groups using negative binomial regression. Results. We identified 149 elite controllers (0.4%) among 34 354 persons in care. Unadjusted hospitalization rates among the medical control, elite control, low-viremia, and high-viremia groups were 10.5, 23.3, 12.6, and 16.9 per 100 person-years, respectively. After adjustment for demographic and clinical factors, elite control was associated with higher rates of all-cause (adjusted incidence rate ratio, 1.77 [95% confidence interval, 1.21-2.60]), cardiovascular (3.19 [1.50-6.79]) and psychiatric (3.98 [1.54-10.28]) hospitalization than was medical control. Non- AIDS-defining infections were the most common reason for admission overall (24.1% of hospitalizations) but were rare among elite controllers (2.7%), in whom cardiovascular hospitalizations were most common (31.1%). Conclusions. Elite controllers are hospitalized more frequently than persons with medically controlled HIV and cardiovascular hospitalizations are an important contributor. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Impact of Hepatitis Coinfection on Hospitalization Rates and Causes in a Multicenter Cohort of Persons Living With HIV.
- Author
-
Crowell, Trevor A., Gebo, Kelly A., Balagopal, Ashwin, Fleishman, John A., Agwu, Allison L., and Berry, Stephen A.
- Abstract
Chronic viral hepatitis is a potentially important determinant of health care utilization among persons living with HIV. We describe hospitalization rates and reasons for hospitalization among persons living with HIV stratified by coinfection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV).Laboratory, demographic, and hospitalization data were obtained for all patients receiving longitudinal HIV care during 2010 at 9 geographically diverse sites. Hepatitis serostatus was assessed by hepatitis B surface antigen and/or hepatitis C antibody. ICD-9 codes were used to assign hospitalizations into diagnostic categories. Negative binomial regression was used to assess factors associated with all-cause and diagnostic category-specific hospitalizations.A total of 2793 hospitalizations were observed among 12,819 patients. Of these patients, 49.3% had HIV monoinfection, 4.1% HIV/HBV, 15.4% HIV/HCV, 2.5% HIV/HBV/HCV, and 28.7% unknown hepatitis serostatus. Compared with HIV monoinfection, the risk of all-cause hospitalization was increased with HIV/HBV [adjusted incidence rate ratio 1.55 (1.17 to 2.06)], HIV/HCV [1.45 (1.21 to 1.74)], and HIV/HBV/HCV [1.52 (1.04 to 2.22)]. Risk of hospitalization for non-AIDS-defining infection was also higher among patients with HIV/HBV [2.07 (1.38 to 3.11)], HIV/HCV [1.81 (1.36 to 2.40)], and HIV/HBV/HCV [1.96 (1.11 to 3.46)]. HIV/HBV was associated with hospitalization for gastrointestinal/liver disease [2.55 (1.30 to 5.01)]. HIV/HCV was associated with hospitalization for psychiatric illness [1.89 (1.11 to 3.26)].HBV and HCV coinfection are associated with increased risk of all-cause hospitalization and hospitalization for non-AIDS-defining infections, as compared with HIV monoinfection. Policy-makers and third-party payers should be aware of the heightened risk of hospitalization associated with coinfection when allocating health care resources and considering models of health care delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. The Impact of Combined Antiretroviral Therapy on Biologic False-Positive Rapid Plasma Reagin Serologies in a Longitudinal Cohort of HIV-Infected Persons.
- Author
-
Oboho, Ikwo K., Gebo, Kelly A., Moore, Richard D., and Ghanem, Khalil G.
- Subjects
- *
ANTIRETROVIRAL agents , *SEROLOGY , *HIV infections , *THERAPEUTICS , *B cells , *IMMUNOSUPPRESSION , *MEDICAL statistics - Abstract
We found that combined antiretroviral therapy is associated with decreased odds of biologic false-positive reactions in persons with human immunodeficiency virus, perhaps as a result of improved B-cell function.Background. Our objective was to determine the impact of combination antiretroviral therapy (cART) and the degree of immunosuppression on biologic false-positive (BFP) rapid plasma reagin (RPR) tests among persons infected with human immunodeficiency virus (HIV).Methods. This was a nested retrospective study of HIV-infected patients enrolled in the Johns Hopkins HIV Clinical Cohort. BFP RPR was defined as a reactive RPR and a nonreactive fluorescent treponemal antibody-absorption (FTA-ABS) test. Patients with BFP tests were compared to 2 control groups: HIV-infected patients (1) with active syphilis (reactive RPR and FTA-ABS) and (2) without current syphilis (nonreactive RPR). A persistent BFP test was defined by having at least 2 visits with consistent BFP at all visits.Results. Of 711 patients with HIV, 96 (13.5%) had BFP tests and 342 (48.1%) had syphilis. Twenty-two of 96 (23%) had persistent BFP tests. cART use was associated with decreased odds of BFP tests compared to having syphilis (adjusted odds ratio [AOR], 0.31; 95% CI, .15–.63) and those with nonreactive RPR (AOR, 0.42; 95% CI, .22–.81). cART use was also associated with decreased odds of BFP persistence (AOR, 0.07; 95% CI, .01–.33). Neither CD4 count nor HIV RNA was significantly associated with BFP test results. Lower RPR titers, younger age, and injection drug use were associated with increased odds of BFP.Conclusions. The use of cART appears to decrease the odds of BFP RPR tests. This finding suggests that nontreponemal titer fluctuations in persons with HIV may reflect the influence of factors unrelated to syphilis disease activity. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network.
- Author
-
Gebo, Kelly, Voss, Cindy, and Mrus, Joseph
- Subjects
- *
PATIENTS , *ETRAVIRINE (Drug) , *HIV , *DARUNAVIR , *ANTIRETROVIRAL agents - Abstract
This observational analysis examined the clinical outcomes of patients receiving etravirine-(ETR-) based therapy, particularly with protease inhibitors (Pis) other than darunavir (DRV) and with raltegravir (RAL). Data included treatment-experienced adults in the HIV Research Network who began ETR-containing antiretroviral regimens in 2008-2010. The primary objective was to assess 6-month outcomes (durability, i.e., still on an ETR-containing regimen; change in CD4+ cell count and HIV-1 RNA <400 copies/mL). The cohort included 587 patients receiving ETR; 42% of ETR use was in patients not on DRV/ritonavir (r). Patients receiving ETR plus DRV/r had longer durability versus those on ETR plus a PI other than DRV/r at months 6 (91.2% versus 85.5%) and 12 (77.4% versus 65.2%), respectively. Patients on regimens with a PI other than DRV/r were the least likely to be receiving ETR at month 6 (85.5%) versus patients on other ETR-based regimens. Patients on regimens without a PI and without RAL had lower virologic suppression (month 6, 54.2%; month 12, 63.2%) versus patients on other ETR-based regimens. In a clinical care, nontrial setting, ETR was used in regimens without DRV/r. In this population, the 6-month response rates were similar and durable across all regimens, except when ETR was used without RAL and without a PI. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
- Author
-
Hill, Andrew M, Gebo, Kelly, Hemmett, Lindsay, Löthgren, Mickael, Allegri, Gabriele, and Smets, Erik
- Abstract
Background: Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts.Objectives: To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI) darunavir on the direct costs of care, while accounting for CD4 cell counts, during the first year of therapy in highly treatment-experienced, HIV-infected adults in different healthcare settings.Methods: The mean annual per-patient cost of darunavir/ritonavir (DRV/r) and control PI-based highly active antiretroviral therapy (HAART) was calculated from the proportional use of antiretroviral agents in the DRV/r and control PI arms of the pooled POWER 1 and 2 trials, applying drug-acquisition costs for five healthcare settings. Non-antiretroviral-related costs by CD4 cell count, derived from non-interventional studies in the same settings, were applied to the POWER data (proportion of patients with CD4 cell counts in different strata at week 48) to estimate mean annual non-antiretroviral-related costs per patient in patients receiving DRV/r or control PI-based HAART during year 1.Results: Across all settings, the mean annual per-patient cost of DRV/r-based treatment was 2-19% higher than that of control PI-based therapy during the first year of therapy. By raising CD4 cell counts, however, DRV/r-based regimens were predicted to lower mean annual non-antiretroviral-related costs by 16-38% compared with control PI-based therapy. When combined, the total annual per-patient cost of HIV care during the first year of therapy was estimated to be 7% lower in the DRV/r compared with the control PI arm using US data, 8% lower using Swedish data, budget neutral using UK and Belgian data and 5% higher using Italian data.Conclusions: Darunavir-based HAART may lower non-antiretroviral-related costs compared with control PI-based therapy in highly treatment-experienced, HIV-infected patients during the first year of therapy by improving patients' CD4 cell counts. These costs could partly/fully offset the increased acquisition cost of DRV/r in this patient population over the same period. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
10. Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts: Evidence from POWER.
- Author
-
Hill, Andrew M., Gebo, Kelly, Hemmett, Lindsay, Löthgren, Mickael, Allegri, Gabriele, and Smets, Erik
- Subjects
- *
COST accounting , *MEDICAL care costs , *HIV-positive persons , *THERAPEUTICS , *HIV infections , *HIGHLY active antiretroviral therapy , *CD4 antigen - Abstract
Background: Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts. Objectives: To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI) darunavir on the direct costs of care, while accounting for CD4 cell counts, during the first year of therapy in highly treatment-experienced, HIV-infected adults in different healthcare settings. Methods: The mean annual per-patient cost of darunavir/ritonavir (DRV/r) and control PI-based highly active antiretroviral therapy (HAART) was calculated from the proportional use of antiretroviral agents in the DRV/r and control PI arms of the pooled POWER 1 and 2 trials, applying drug-acquisition costs for five healthcare settings. Non-antiretroviral-related costs by CD4 cell count, derived from non-interventional studies in the same settings, were applied to the POWER data (proportion of patients with CD4 cell counts in different strata at week 48) to estimate mean annual nonantiretroviral- related costs per patient in patients receiving DRV/r or control PI-based HAART during year 1. Results: Across all settings, the mean annual per-patient cost of DRV/r-based treatment was 2-19% higher than that of control PI-based therapy during the first year of therapy. By raising CD4 cell counts, however, DRV/r-based regimens were predicted to lower mean annual non-antiretroviral-related costs by 16-38% compared with control PI-based therapy. When combined, the total annual per-patient cost of HIV care during the first year of therapy was estimated to be 7%lower in the DRV/r compared with the control PI arm using US data, 8% lower using Swedish data, budget neutral using UK and Belgian data and 5% higher using Italian data. Conclusions: Darunavir-based HAART may lower non-antiretroviral-related costs compared-with control PI-based therapy in highly treatment-experienced, HIV-infected patients during the first year of therapy by improving patients' CD4 cell counts. These costs could partly/fully offset the increased acquisition cost of DRV/r in this patient population over the same period. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts.
- Author
-
Hill, Andrew M., Gebo, Kelly, Hemmett, Lindsay, Löthgren, Mickael, Allegri, Gabriele, and Smets, Erik
- Subjects
- *
HIV infections , *MEDICAL care costs , *HIGHLY active antiretroviral therapy , *CLINICAL trials , *PROTEASE inhibitors - Abstract
Background: Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts. Objectives: To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI) darunavir on the direct costs of care, while accounting for CD4 cell counts, during the first year of therapy in highly treatment-experienced, HIV-infected adults in different healthcare settings. Methods: The mean annual per-patient cost of darunavir/ritonavir (DRV/r) and control PI-based highly active antiretroviral therapy (HAART) was calculated from the proportional use of antiretroviral agents in the DRV/r and control PI arms of the pooled POWER 1 and 2 trials, applying drugacquisition costs for five healthcare settings. Non-antiretroviral-related costs by CD4 cell count, derived from non-interventional studies in the same settings, were applied to the POWER data (proportion of patients with CD4 cell counts in different strata at week 48) to estimate mean annual nonantiretroviral- related costs per patient in patients receiving DRV/r or control PI-based HAART during year 1. Results: Across all settings, the mean annual per-patient cost of DRV/r-based treatment was 2-19% higher than that of control PI-based therapy during the first year of therapy. By raising CD4 cell counts, however, DRV/r-based regimens were predicted to lower mean annual non-antiretroviral-related costs by 16-38% compared with control PI-based therapy. When combined, the total annual per-patient cost of HIV care during the first year of therapy was estimated to be 7%lower in the DRV/r compared with the control PI arm using US data, 8% lower using Swedish data, budget neutral using UK and Belgian data and 5% higher using Italian data. Conclusions: Darunavir-based HAART may lower non-antiretroviral-related costs comparedwith control PI-based therapy in highly treatment-experienced, HIV-infected patients during the first year of therapy by improving patients' CD4 cell counts. These costs could partly/fully offset the increased acquisition cost of DRV/r in this patient population over the same period. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
12. CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?
- Author
-
Althoff, Keri N., Gebo, Kelly A., Gange, Stephen J., Klein, Marina B., Brooks, John T., Hogg, Robert S., Bosch, Ronald J., Horberg, Michael A., Saag, Michael S., Kitahata, Mari M., Eron, Joseph J., Napravnik, Sonia, Rourke, Sean B., Gill, M. John, Rodriguez, Benigno, Sterling, Timothy R., Deeks, Steven G., Martin, Jeffrey N., Jacobson, Lisa P., and Kirk, Gregory D.
- Subjects
- *
HIV infections , *MEDICAL care , *AIDS - Abstract
We assessed CD4 count at initial presentation for HIV care among ≥50-year-olds from 1997-2007 in 13 US and Canadian clinical cohorts and compared to <50-year-olds. 44,491 HIV-infected individuals in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) were included in our study. Trends in mean CD4 count (measured as cells/mm³) and 95% confidence intervals ([,]) were determined using linear regression stratified by age category and adjusted for gender, race/ethnicity, HIV transmission risk and cohort. From 1997-2007, the proportion of individuals presenting for HIV care who were ≥50-years-old increased from 17% to 27% (p-value < 0.01). The median CD4 count among ≥50 year-olds was consistently lower than younger adults. The interaction of age group and calendar year was significant (p-value <0.01) with both age groups experiencing modest annual improvements over time (< 50-year-olds: 5[4 , 6] cells/mm³; ≥50-year-olds: 7[5 , 9] cells/mm³), after adjusting for sex, race/ethnicity, HIV transmission risk group and cohort; however, increases in the two groups were similar after 2000. A greater proportion of older individuals had an AIDS-defining diagnosis at, or within three months prior to, first presentation for HIV care compared to younger individuals (13% vs. 10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
13. PUBLIC HEALTH STUDIES AS AN UNDERGRADUATE MAJOR.
- Author
-
GEBO, KELLY A., GOODYEAR, JAMES D., DAVID, STEVEN R., and YAGER, JAMES D.
- Subjects
- *
PUBLIC health education , *HEALTH education , *UNDERGRADUATE programs , *COLLEGE curriculum , *CONTINUING legal education ,STUDY & teaching of medicine - Abstract
The article discusses the prevalence of public health studies (PHS) as an undergraduate major. The undergraduate PHS is said to be a four-year bachelor of arts (BA) program. It is said that it prepares students for advanced studies in the fields such as public health, law and medicine. Schools that offer PHS are said to include Johns Hopkins University (JHU), George Washington University (GWU) and Loma Linda University (LLU).
- Published
- 2008
- Full Text
- View/download PDF
14. Venous Thromboembolism in Patients With HIV/AIDS.
- Author
-
Ahonkhai, Aima A., Gebo, Kelly A., Streiff, Michael B., Moore, Richard D., and Segal, Jodi B.
- Subjects
- *
THROMBOEMBOLISM , *HIV infections , *AIDS , *DISEASE risk factors , *HIV-positive persons - Abstract
The article investigates the prevalence of established risk factors for venous thromboembolism (VTE) in HIV-infected patients, and explores novel risk factors. It shows that the incidence of VTE in the cohort is similar to that reported in other cohorts of patients with HIV. The article provides evidence that recent hospitalization is the risk factor most strongly associated with VTE.
- Published
- 2008
- Full Text
- View/download PDF
15. A Ten-Year Analysis of the Incidence and Risk Factors for Acute Pancreatitis Requiring Hospitalization in an Urban HIV Clinical Cohort.
- Author
-
Riedel, David J., Gebo, Kelly A., Moore, Richard D., and Lucas, Gregory M.
- Subjects
- *
PANCREATITIS , *HOSPITAL care , *HIV-positive persons , *ANTIVIRAL agents , *IMMUNOSUPPRESSION , *NUCLEOSIDES , *PANCREATIC diseases , *ANTIRETROVIRAL agents , *PROTEASE inhibitors - Abstract
To assess the incidence of and risk factors for acute pancreatitis in HIV-infected patients in the contemporary highly active antiretroviral therapy (HAART) era, we evaluated all cases of acute pancreatitis requiring hospitalization between 1996 and 2006 in patients followed at Johns Hopkins Hospital's HIV clinic. A nested, case-control analysis was employed for initial episodes of acute pancreatitis, and conditional logistic regression was used to assess risk factors. Of 5970 patients followed for 23,460 person–years (PYs), there were 85 episodes of acute pancreatitis (incidence: 3.6 events/1000 PYs). The incidence of pancreatitis from 1996 to 2000 was 2.6 events/1000 PYs; the incidence from 2001 to 2006 was 5.1 events/1000 PYs ( p = 0.0014, comparing rates in two time periods). In multivariate regression, factors associated with pancreatitis included female gender (adjusted odds ratio [AOR] 2.96 [1.69, 5.19]; p < 0.001); stavudine use (AOR 2.19 [1.16, 4.15]; p = 0.016); aerosolized pentamidine use (OR 6.27; [1.42, 27.63]; p = 0.015); and CD4 count less than 50 cells/mm3 (AOR 10.47 [3.33, 32.90]; p < 0.001). Race/ethnicity, HIV risk factor, HIV-1 RNA, and newer non-nucleoside reverse transcriptase inhibitors (NNRTI)- and protease inhibitor (PI)-based HAART regimens were not associated with an increased risk of pancreatitis after adjustment for the above factors. Pancreatitis remains a significant cause of morbidity in the HIV population in the HAART era. Acute pancreatitis is associated with female gender, severe immunosuppression, and stavudine and aerosolized pentamidine usage. Of note, newer antiretrovirals, particularly atazanavir, lopinivir/ritonavir, tenofovir, abacavir, and efavirenz, were not associated with an increased risk of pancreatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. HIV and Aging: Implications for Patient Management.
- Author
-
Gebo, Kelly A.
- Subjects
- *
PATIENTS , *HIV infections , *HIV-positive persons , *ANTIRETROVIRAL agents , *DISEASES in older people , *DRUG interactions - Abstract
Between 2001 and 2004, the percentage of all HIV cases in patients aged ≥50 years increased from 17% to 23%. This concerning increase is expected to continue over the next decade. The increasing prevalence of HIV in these patients is a result of increased longevity in patients treated with highly active antiretroviral therapy (HAART) as well as new primary infections in older patients. While older patients may achieve virological suppression at the same rate as younger patients, the immunological benefit of HAART in older patients may be reduced compared with younger patients. In addition, the toxicities associated with HAART may be worse in older HIV patients, particularly those with underlying renal or hepatic insufficiency. All previous studies evaluating the virological and immunological benefits of HAART in older patients have had relatively small sample sizes and none has compared efficacy or rates of toxicity by HAART treatment class. Co-morbidities are more common in older than in younger patients and can impact on the management of HIV in these patients. Providers must be cognisant of drug-drug interactions and potential adverse effects of HAART regimens when selecting an ideal antiretroviral regimen for older HIV patients. Given the increased longevity and rates of malignancies in HIV-infected patients, providers should also be particularly vigilant in maintaining routine health screening in older HIV patients. Controlled trials on HIV epidemiology, pathogenesis, and therapeutic and clinical outcomes are also needed in older patients. As the HIV-infected population ages, there is a growing need to better determine the effectiveness of HAART in older patients, and to investigate factors associated with a more rapid course of HIV infection in patients aged >50 years. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
17. Hospitalizations for Metabolic Conditions, Opportunistic Infections, and Injection Drug Use Among HIV Patients Trends Between 7996 and 2000 in 72 States.
- Author
-
Gebo, Kelly A., Fleishman, John A., and Moore, Richard D.
- Subjects
- *
AIDS prevention , *HIV infections , *OPPORTUNISTIC infections , *HIV-positive persons , *HOSPITAL care , *DIABETES complications , *ANTIVIRAL agents , *PUBLIC health - Abstract
The article focuses on the hospitalizations for metabolic conditions, opportunistic infections and injection drug use among HIV patients in 72 states. Rapid changes in HIV epidemiology and highly active antiretroviral therapy (HAART) result in inpatient utilization. The objectives is to examine trends in inpatient diagnoses and mortality in HIV patients. Each hospitalization was classified as an opportunistic illness, complication of injection drug use, liver-related complication, and diabetes.
- Published
- 2005
- Full Text
- View/download PDF
18. The Incidence of, Risk Factors for, and Sequelae of Herpes Zoster Among HIV Patients in the Highly Active Antiretroviral Therapy Era.
- Author
-
Gebo, Kelly A., Kalyani, Rita, Moore, Richard D., and Polydefkis, Michael J.
- Subjects
- *
HERPES zoster , *HERPESVIRUS diseases , *INCIDENCE functions , *DISEASE risk factors , *PATIENTS , *NEURALGIA , *INFECTION - Abstract
Cites a study about the incidence, risk factors and clinical sequelae of herpes zoster. Significance of the patients percentage with post-herpetic neuralgia on the zoster infection rates changes; Identification of patients with episode of herpes zoster; Assessment of factors associated with an initial episode of herpes zoster.
- Published
- 2005
- Full Text
- View/download PDF
19. Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Persist in a Multistate Sample of HIV Patients in 2001.
- Author
-
Gebo, Kelly A., Fleishman, John A., Conviser, Richard, Reilly, Erin D., Korthuis, Todd, Moore, Richard D., Hellinger, James, Keiser, Philip, Rubin, Haya R., Crane, Lawrence, Hellinger, Fred J., and Christopher Mathews, W.
- Subjects
- *
ANTIRETROVIRAL agents , *DRUG utilization , *HIV infections , *HIV-positive women , *HIV infection transmission - Abstract
Examines demographic and clinical differences associated with receipt of highly active antiretroviral therapy (HAART) and the association of outpatient utilization with HAART. Redaction of persistent disparities in women; Evidence for racial and ethnic disparities in the receipt of antiretroviral therapy; Risk factors for HIV transmission.
- Published
- 2005
- Full Text
- View/download PDF
20. Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of Opportunistic Illness in HIV Infection.
- Author
-
Gebo, Kelly A., Gallant, Joel E., Keruly, Jeanne C., and Moore, Richard D.
- Subjects
- *
THERAPEUTICS , *AIDS patients , *HIV-positive persons , *OPPORTUNISTIC infections , *REGRESSION analysis , *MEDICAL care - Abstract
Reports on recommended guidelines for consideration of CD4 cell percentage as well as CD4 cell count in therapeutic decisions for AIDS patients. Prediction of the risk of AIDS-defining illnesses (ADI); Assessment of the incidence of ADI ; Computation of the incidence ratio rate with the use of multivariable negative binomial regression.
- Published
- 2004
- Full Text
- View/download PDF
21. The Epidemiology, Treatment Patterns, and Costs of Cytomegalovirus Retinitis in the Post-HAART Era Among a National Managed-Care Population.
- Author
-
Mahadevia, Parthiv J., Gebo, Kelly A., Pettit, Krista, Dunn, J.P., and Covington, Melva T.
- Subjects
- *
CYTOMEGALOVIRUS diseases , *ANTIVIRAL agents , *EPIDEMIOLOGY , *HIV infections , *AIDS , *DIAGNOSIS - Abstract
Reports on a retrospective cohort study performed using data from U.S. managed care plans from 1997 to 2002 to examine the epidemiology, treatment patterns and costs of cytomegalovirus (CMV) retinitis treatment in the post-highly active antiretroviral therapy (HAART) era. Definition of cases of CMV retinitis by requiring diagnosis codes for HIV or AIDS, CMV and retinitis and claims for anti-CMV treatment; Examination of costs of oral, intravenous and intraocular treatment periods.
- Published
- 2004
- Full Text
- View/download PDF
22. Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort.
- Author
-
Gebo, Kelly A., Diener-West, Marie, and Moore, Richard D.
- Subjects
- *
HIV-positive persons , *HEPATITIS C , *DISEASES - Abstract
Studies whether hepatitis C virus infection status affected hospitalization rates, intensive care utilization and discharge diagnoses between 1995 and 2000 in patients with HIV. Reduction of mortality and morbidity in HIV infected patients through highly active antiretroviral therapy.
- Published
- 2003
- Full Text
- View/download PDF
23. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.
- Author
-
Gebo, Kelly A., Keruly, Jeanne, and Moore, Richard D.
- Subjects
- *
ANTIVIRAL agents , *MEDICAL care of HIV-positive persons , *PATIENT compliance , *HEALTH behavior , *COMPARATIVE studies , *HEALTH attitudes , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *SOCIAL classes , *PSYCHOLOGICAL stress , *SUBSTANCE abuse , *LOGISTIC regression analysis , *SOCIAL support , *EVALUATION research , *CROSS-sectional method , *PATIENT refusal of treatment , *ANTI-HIV agents , *ODDS ratio , *PSYCHOLOGY ,SOCIAL aspects ,HIV infections & psychology - Abstract
Objective: To assess the roles of socioeconomic status, social stability, social stress, health beliefs, and illicit drug use with nonadherence to antiretroviral therapy.Design: Cross-sectional study.Setting: Urban hospital clinic.Participants: One hundred ninety-six consecutive HIV-infected patients taking at least 1 antiretroviral medication, awaiting a visit with their primary care provider.Methods: Patients were interviewed while waiting for a clinic appointment and were asked to fill out a 4-part survey with questions regarding antiretroviral adherence, illicit drug use, health beliefs, and social situation. Adherence was defined as the percentage of doses taken, i.e., the number of doses taken divided by the number of doses prescribed over a 2-week interval. Univariate and multivariate logistic regressions were performed to identify factors associated with nonadherence in different patient subgroups.Main Results: Nonadherence to antiretroviral therapy was associated with active illicit drug use (adjusted odds ratio [AOR], 2.31; 95% confidence interval [95% CI], 1.17 to 4.58), eating fewer than 2 meals per day (AOR, 3.31; 95% CI, 1.11 to 9.92), and feeling as though pressures outside of the clinic affected patient's ability to take antiretroviral medications as prescribed (AOR, 2.22; 95% CI, 0.99 to 4.97). In patients with a history of injection drug use, nonadherence to antiretroviral therapy was independently associated with eating fewer than 2 meals per day (AOR, 17.54; 95% CI, 1.92 to 160.4) and active illicit drug use (AOR, 4.18; 95% CI, 1.68 to 10.75). In patients without any injection drug use, nonadherence was only associated with feeling as though pressures outside of clinic affected patient's ability to take antiretroviral medications as prescribed (AOR, 3.55; 95% CI, 1.07 to 11.76). Male-to-male sexual contact was associated with lower nonadherence in patients with an HIV risk factor other than injection drug use (AOR, 0.35; 95% CI, 0.13 to 0.95). A history of drug use but no illicit drug use within 6 months of the interview was not associated with an increased rate of nonadherence.Conclusions: Although our sample size was limited and variables that are not significant in subgroup analysis may still be associated with adherence, our results suggest that correlates of nonadherence are HIV risk factor specific. Strategies to increase antiretroviral adherence in HIV-infected patients should include social support interventions targeted at different risk factors for different patient groups. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
24. Pseudo-outbreak of Mycobacterium fortuitum on a Human Immunodeficiency Virus Ward: Transient Respiratory Tract Colonization from a Contaminated Ice Machine.
- Author
-
Gebo, Kelly A., Srinivasan, Arjun, Perl, Trish M., Ross, Tracy, Groth, Amy, and Merz, William G.
- Subjects
- *
MYCOBACTERIUM , *HIV-positive persons , *DISEASES - Abstract
Infection Control surveillance revealed an abnormally high number of sputum samples growing Mycobacterium fortuitum from a single ward that houses the human immunodeficiency virus service. We investigated the outbreak using a retrospective case-control study and molecular epidemiology. A total of 47 patients were identified with ≥1 sputum sample that grew M. fortuitum. No significant demographic or clinical variables were found to be associated with colonization. Environmental investigation demonstrated that the M. fortuitum isolated from patients was identical to the ice machine isolates by pulsed-field gel electrophoresis. Fortunately, there has been no evidence of progressive pulmonary disease developing in our patients after ≥6 months of follow-up. All cases were thought to represent transient colonization and not infection. The ice machine was disconnected and cleaned successfully with vinegar and then bleach. Only when a 0.5-µm filter was installed were no further patients colonized or water cultures found to be positive. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
25. Hospitalization Rates in an Urban Cohort After the Introduction of Highly Active Antiretroviral Therapy.
- Author
-
Gebo, Kelly A., Diener-West, Marie, and Moore, Richard D.
- Subjects
- *
HIV-positive persons , *HOSPITAL utilization , *HOSPITAL admission & discharge , *HOSPITAL care - Abstract
Evaluates the hospitalization rates and patterns in discharge diagnosis among HIV-positive patients in the United States between 1995 and 1998. Risk factors for hospitalization; Characteristics of the study population; Impact of the introduction of highly active antiretroviral therapy on the rate of hospitalization.
- Published
- 2001
- Full Text
- View/download PDF
26. Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation.
- Author
-
Lang, Raynell, Coburn, Sally B., Gill, M. John, Justice, Amy C., Grossman, Jennifer, Gebo, Kelly A., Horberg, Michael A., Mayor, Angel M., Silverberg, Michael J., McGinnis, Kathleen A., Hogan, Brenna, Moore, Richard D., and Althoff, Keri N.
- Subjects
- *
HYPERTENSION risk factors , *ANEMIA , *RISK assessment , *POISSON distribution , *REPEATED measures design , *ANTIRETROVIRAL agents , *ERYTHROCYTES , *RESEARCH funding , *SEX distribution , *HIV-positive persons , *HIV infections , *DESCRIPTIVE statistics , *DISEASE prevalence , *COMPARATIVE studies , *MACROCYTIC anemia , *CONFIDENCE intervals , *DISEASE risk factors - Abstract
Background: Anemia is common and associated with increased morbidity among people with HIV (PWH). Classification of anemia using the mean corpuscular volume (MCV) can help investigate the underlying causative factors of anemia. We characterize anemia using MCV among PWH receiving antiretroviral therapy (ART), and identify the risk factors for normocytic, macrocytic, and microcytic anemias. Methods: Including PWH with anemia (hemoglobin measure < 12.9 g/dL among men and < 11.9 g/dL among women) in the NA-ACCORD from 01/01/2007 to 12/31/2017, we estimated the annual distribution of normocytic (80–100 femtolitre (fL)), macrocytic (> 100 fL) or microcytic (< 80 fL) anemia based on the lowest hemoglobin within each year. Poisson regression models with robust variance and general estimating equations were used to estimate crude and adjusted prevalence ratios and 95% confidence intervals for risk factors for macrocytic (vs. normocytic) and microcytic (vs. normocytic) anemia stratified by sex. Results: Among 37,984 hemoglobin measurements that identified anemia in 14,590 PWH, 27,909 (74%) were normocytic, 4257 (11%) were microcytic, and 5818 (15%) were macrocytic. Of the anemic PWH included over the study period, 1910 (13%) experienced at least one measure of microcytic anemia and 3208 (22%) at least one measure of macrocytic anemia. Normocytic anemia was most common among both males and females, followed by microcytic among females and macrocytic among males. Over time, the proportion of anemic PWH who have macrocytosis decreased while microcytosis increased. Macrocytic (vs. normocytic) anemia is associated with increasing age and comorbidities. With increasing age, microcytic anemia decreased among females but not males. A greater proportion of PWH with normocytic anemia had CD4 counts ≤ 200 cells/mm3 and had recently initiated ART. Conclusion: In anemic PWH, normocytic anemia was most common. Over time macrocytic anemia decreased, and microcytic anemia increased irrespective of sex. Normocytic anemia is often due to chronic disease and may explain the greater risk for normocytic anemia among those with lower CD4 counts or recent ART initiation. Identified risk factors for type-specific anemias including sex, age, comorbidities, and HIV factors, can help inform targeted investigation into the underlying causes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. A pilot study of peer review in residency training.
- Author
-
Thomas, Patricia A., Gebo, Kelly A., Hellmann, David B., Thomas, P A, Gebo, K A, and Hellmann, D B
- Subjects
- *
PROFESSIONAL peer review , *INTERNAL medicine , *HEALTH boards - Abstract
Objective: To explore the utility of peer review (review by fellow interns or residents in the firm) as an additional method of evaluation in a university categorical internal medicine residency program.Design/participants: Senior residents and interns were asked to complete evaluations of interns at the end-of-month ward rotations.Main Results: Response rates for senior residents evaluating 16 interns were 70%; for interns evaluating interns, 35%. Analysis of 177 instruments for 16 interns showed high internal consistency in the evaluations. Factor analysis supported a two-dimensional view of clinical competence. Correlations between faculty, senior resident, and intern assessments of interns were good, although varied by domain.Conclusions: An end-of-year attitude survey found that residents gave high ratings to the value of feedback from peers. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
28. CD4 T-Lymphocyte Percentages Corresponding to CD4 T-Lymphocyte Count Thresholds in a New Staging System for HIV Infection.
- Author
-
Selik, Richard M., Gebo, Kelly A., Borkowf, Craig B., Whitmore, Suzanne K., and Espinoza, Lorena
- Published
- 2014
- Full Text
- View/download PDF
29. Rate of Comorbidities Not Related to HIV Infection or AIDS among HIV-Infected Patients, by CD4 Cell Count and HAART Use Status.
- Author
-
Moore, Richard D., Gebo, Kelly A., Lucas, Gregory M., and Keruly, Jeanne C.
- Subjects
- *
CD4 antigen , *DISEASE risk factors , *DISEASE incidence , *AIDS patients , *AIDS-related opportunistic infections , *HIGHLY active antiretroviral therapy , *IMMUNOSUPPRESSION , *CLINICAL medicine , *CLINICAL trials - Abstract
The rate of comorbidities not related to human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) among HIV-infected patients may be higher than expected. We assessed the incidence of comorbidities not related to HIV infection or AIDS by CD4 cell count and highly active antiretroviral therapy (HAART) use status in an HIV clinical practice. A total of 2824 patients contributed 9172 person-years of longitudinal data during the period 1997-2006. Among patients with a CD4 cell count <350 cells/mm[sup3], receipt of HAART was associated with a significantly decreased incidence of comorbidities not related to HIV infection or AIDS. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
30. Orthopoxvirus-Specific T-Cell Responses in Convalescent Mpox Patients.
- Author
-
Traut, Caroline C, Jones, Joyce L, Sanders, Renata A, Clark, Laura R, Hamill, Matthew M, Stavrakis, Georgia, Sop, Joel, Beckey, Tyler P, Keller, Sara C, Gilliams, Elizabeth A, Cochran, Willa V, Laeyendecker, Oliver, Manabe, Yukari C, Mostafa, Heba H, Thomas, David L, Hansoti, Bhakti, Gebo, Kelly A, and Blankson, Joel N
- Subjects
- *
MONKEYPOX , *T cells , *VACCINIA , *HIV , *IMMUNOSUPPRESSIVE agents - Abstract
Orthopoxvirus-specific T-cell responses were analyzed in 10 patients who had recovered from Mpox including 7 people with human immunodeficiency virus (PWH). Eight participants had detectable virus-specific T-cell responses, including a PWH who was not on antiretroviral therapy and a PWH on immunosuppressive therapy. These 2 participants had robust polyfunctional CD4+ T-cell responses to peptides from the 121L vaccinia virus (VACV) protein. T-cells from 4 of 5 HLA-A2–positive participants targeted at least 1 previously described HLA-A2–restricted VACV epitope, including an epitope targeted in 2 participants. These results advance our understanding of immunity in convalescent Mpox patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study.
- Author
-
Althoff, Keri N., Stewart, Cameron, Humes, Elizabeth, Gerace, Lucas, Boyd, Cynthia, Gebo, Kelly, Justice, Amy C., Hyle, Emily P., Coburn, Sally B., Lang, Raynell, Silverberg, Michael J., Horberg, Michael A., Lima, Viviane D., Gill, M. John, Karris, Maile, Rebeiro, Peter F., Thorne, Jennifer, Rich, Ashleigh J., Crane, Heidi, and Kitahata, Mari
- Subjects
- *
HIV-positive persons , *MYOCARDIAL infarction , *HETEROSEXUALS , *HIV seroconversion , *DRUG abuse , *MEDICAL personnel , *COMORBIDITY - Abstract
Background: Estimating the medical complexity of people aging with HIV can inform clinical programs and policy to meet future healthcare needs. The objective of our study was to forecast the prevalence of comorbidities and multimorbidity among people with HIV (PWH) using antiretroviral therapy (ART) in the United States (US) through 2030. Methods and findings: Using the PEARL model—an agent-based simulation of PWH who have initiated ART in the US—the prevalence of anxiety, depression, stage ≥3 chronic kidney disease (CKD), dyslipidemia, diabetes, hypertension, cancer, end-stage liver disease (ESLD), myocardial infarction (MI), and multimorbidity (≥2 mental or physical comorbidities, other than HIV) were forecasted through 2030. Simulations were informed by the US CDC HIV surveillance data of new HIV diagnosis and the longitudinal North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) data on risk of comorbidities from 2009 to 2017. The simulated population represented 15 subgroups of PWH including Hispanic, non-Hispanic White (White), and non-Hispanic Black/African American (Black/AA) men who have sex with men (MSM), men and women with history of injection drug use and heterosexual men and women. Simulations were replicated for 200 runs and forecasted outcomes are presented as median values (95% uncertainty ranges are presented in the Supporting information). In 2020, PEARL forecasted a median population of 670,000 individuals receiving ART in the US, of whom 9% men and 4% women with history of injection drug use, 60% MSM, 8% heterosexual men, and 19% heterosexual women. Additionally, 44% were Black/AA, 32% White, and 23% Hispanic. Along with a gradual rise in population size of PWH receiving ART—reaching 908,000 individuals by 2030—PEARL forecasted a surge in prevalence of most comorbidities to 2030. Depression and/or anxiety was high and increased from 60% in 2020 to 64% in 2030. Hypertension decreased while dyslipidemia, diabetes, CKD, and MI increased. There was little change in prevalence of cancer and ESLD. The forecasted multimorbidity among PWH receiving ART increased from 63% in 2020 to 70% in 2030. There was heterogeneity in trends across subgroups. Among Black women with history of injection drug use in 2030 (oldest demographic subgroup with median age of 66 year), dyslipidemia, CKD, hypertension, diabetes, anxiety, and depression were most prevalent, with 92% experiencing multimorbidity. Among Black MSM in 2030 (youngest demographic subgroup with median age of 42 year), depression and CKD were highly prevalent, with 57% experiencing multimorbidity. These results are limited by the assumption that trends in new HIV diagnoses, mortality, and comorbidity risk observed in 2009 to 2017 will persist through 2030; influences occurring outside this period are not accounted for in the forecasts. Conclusions: The PEARL forecasts suggest a continued rise in comorbidity and multimorbidity prevalence to 2030, marked by heterogeneities across race/ethnicity, gender, and HIV acquisition risk subgroups. HIV clinicians must stay current on the ever-changing comorbidities-specific guidelines to provide guideline-recommended care. HIV clinical directors should ensure linkages to subspecialty care within the clinic or by referral. HIV policy decision-makers must allocate resources and support extended clinical capacity to meet the healthcare needs of people aging with HIV. In this modelling study, Keri N Althoff and colleagues employ an agent-based simulation model to forecast the burden of comorbidity and multimorbidity in individuals who have initiated ART in the US. Author summary: Why was this study done?: Individuals with HIV are aging and are experiencing an increased risk of comorbidities and multimorbidity. Anticipating the healthcare needs of an aging population with HIV is crucial for healthcare providers, policymakers, and public health officials to plan for medical and support services tailored to the unique needs of aging people with HIV. In response to the increasing medical complexity among aging adults with HIV, we employed an agent-based simulation model to forecast the potential burden of comorbidity and multimorbidity in individuals who have initiated antiretroviral therapy (ART) in the US. What did the researchers do and find?: PEARL is an agent-based simulation of persons with HIV who have initiated ART in the US, utilizing data from the CDC HIV surveillance system and comorbidity risk functions derived from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), the largest longitudinal cohort of people with HIV who have linked into care in the US. Following a gradual increase in number of people with HIV receiving ART from 2020 to 2030, PEARL forecasted a population of 908,504 in the US in 2030, and an increase in multimorbidity burden from 63% in 2020 to 70% in 2030 among people with HIV. Although mental health conditions had the highest burden, the mix of physical comorbidities of greatest burden was different by demographic and HIV acquisition risk subgroups. What do these findings mean?: HIV clinicians can use these findings to identify the comorbidity-specific screening, diagnoses, and treatment guidelines and tools that will be necessary to care for their panel of patients. HIV care program decision-makers can use these findings to predict the subspecialities that will be in highest demand by their clinical population and make the connections to subspecialists (bringing them into the HIV clinic or by referral) needed meet the healthcare needs of people with HIV. HIV policy decision-makers can use these findings to guide expansion in subspecialty care capacity (particularly for mental health conditions) and the resources needed for expansion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Hospital Readmissions Among Persons With Human Immunodeficiency Virus in the United States and Canada, 2005–2018: A Collaboration of Cohort Studies.
- Author
-
Davy-Mendez, Thibaut, Napravnik, Sonia, Hogan, Brenna C, Eron, Joseph J, Gebo, Kelly A, Althoff, Keri N, Moore, Richard D, Silverberg, Michael J, Horberg, Michael A, Gill, M John, Rebeiro, Peter F, Karris, Maile Y, Klein, Marina B, Kitahata, Mari M, Crane, Heidi M, Nijhawan, Ank, McGinnis, Kathleen A, Thorne, Jennifer E, Lima, Viviane D, and Bosch, Ronald J
- Subjects
- *
HIV , *PATIENT readmissions , *PSYCHIATRIC hospital care , *CD4 lymphocyte count , *COHORT analysis - Abstract
Background Hospital readmission trends for persons with human immunodeficiency virus (PWH) in North America in the context of policy changes, improved antiretroviral therapy (ART), and aging are not well-known. We examined readmissions during 2005–2018 among adult PWH in NA-ACCORD. Methods Linear risk regression estimated calendar trends in 30-day readmissions, adjusted for demographics, CD4 count, AIDS history, virologic suppression (<400 copies/mL), and cohort. Results We examined 20 189 hospitalizations among 8823 PWH (73% cisgender men, 38% White, 38% Black). PWH hospitalized in 2018 versus 2005 had higher median age (54 vs 44 years), CD4 count (469 vs 274 cells/μL), and virologic suppression (83% vs 49%). Unadjusted 30-day readmissions decreased from 20.1% (95% confidence interval [CI], 17.9%–22.3%) in 2005 to 16.3% (95% CI, 14.1%–18.5%) in 2018. Absolute annual trends were −0.34% (95% CI, −.48% to −.19%) in unadjusted and −0.19% (95% CI, −.35% to −.02%) in adjusted analyses. By index hospitalization reason, there were significant adjusted decreases only for cardiovascular and psychiatric hospitalizations. Readmission reason was most frequently in the same diagnostic category as the index hospitalization. Conclusions Readmissions decreased over 2005–2018 but remained higher than the general population's. Significant decreases after adjusting for CD4 count and virologic suppression suggest that factors alongside improved ART contributed to lower readmissions. Efforts are needed to further prevent readmissions in PWH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Risk Factors for Hospitalization and Effect of Immunosuppression on Clinical Outcomes Among an Urban Cohort of Patients With Mpox.
- Author
-
Garneau, William M, Jones, Joyce L, Dashler, Gabriella M, Mostafa, Heba H, Judson, Seth D, Kwon, Nathan, Hamill, Matthew M, Gilliams, Elizabeth A, Rudolph, David S, Keruly, Jeanne C, Fall, Amary, Klein, Eili Y, Hansoti, Bhakti, and Gebo, Kelly A
- Subjects
- *
MONKEYPOX , *HIV , *TREATMENT effectiveness , *HIV infections , *IMMUNOSUPPRESSION - Abstract
Background During the 2022 mpox outbreak most patients were managed as outpatients, but some required hospitalization. Uncontrolled human immunodeficiency virus (HIV) has been identified as a risk factor for severe mpox. Methods Patients with mpox diagnosed or treated within the Johns Hopkins Health System between 1 June and 15 December 2022 were included. The primary outcome of interest was risk of hospitalization. Demographic features, comorbid conditions, treatment, and clinical outcomes were determined. Results A total of 353 patients were tested or treated for mpox; 100 had mpox diagnosed or treated (median age, 35.3 years; 97.0% male; 57.0% black and 10.0% Hispanic; 46.0% people with HIV [PWH]). Seventeen patients (17.0%) required hospitalization, 10 of whom were PWH. Age >40 years, race, ethnicity, HIV status, insurance status, and body mass index >30 (calculated as weight in kilograms divided by height in meters squared) were not associated with hospitalization. Eight of 9 patients (88.9%) with immunosuppression were hospitalized. Immunosuppression was associated with hospitalization in univariate (odds ratio, 69.3 [95% confidence interval, 7.8–619.7]) and adjusted analysis (adjusted odds ratio, 94.8 [8.5–1060.1]). Two patients (11.8%) who were hospitalized required intensive care unit admission and died; both had uncontrolled HIV infection and CD4 T-cell counts <50/µL. Median cycle threshold values for the first positive mpox virus sample did not differ between those who were hospitalized and those who were not. Conclusions Immunosuppression was a significant risk factor for hospitalization with mpox. PWH with CD4 T-cell counts <50/µL are at high risk of death due to mpox infection. Patients who are immunosuppressed should be considered for early and aggressive treatment of mpox, given the increased risk of hospitalization. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Higher Acuity Resource Utilization With Older Age and Poorer HIV Control in Adolescents and Young Adults in the HIV Research Network.
- Author
-
Neilan, Anne M., Lu, Frances, Gebo, Kelly A., Diaz-Reyes, Rebeca, Mingshu Huang, Parker, Robert A., Karalius, Brad, Patel, Kunjal, Voss, Cindy, Ciaranello, Andrea L., and Agwu, Allison L.
- Abstract
Background: Adolescents and young adults (AYA) with HIV experience poorer health outcomes compared with adults. To improve care for AYA with HIV, information about patterns of costly health care resource utilization is needed. Methods: Among 13-30 year olds in the US HIV Research Network, we stratified outpatient visits, emergency department (ED) visits, and inpatient days/person-year (PY) by HIV acquisition model [perinatal (PHIVY) and nonperinatal (NPHIVY)], age (13-17, 18-23, and 24-30 years), CD4 strata (< 200, 200-499, and ≥500 cells/mL), and viral load (VL) suppression (<, ≥400 copies/mL [c/mL]) combined with antiretroviral (ARV) use. Results: Among 4540 AYA (PHIVY: 15%; NPHIVY: 85%), mean follow-up was 2.8 years. Among PHIVY, most person-time (PT) was spent between ages 13 and 23 years (13-17 years: 43%; 18-23 years: 45%), CD4 ≥500/%#181;L (61%), and VL < 400 c/mL (69%). Among NPHIVY, most PT was spent between ages 24 and 30 years (56%), with CD4 ≥500/µL (54%), and with VL < 400 c/mL (67%). PT spent while prescribed ARVs and with VL ≥400 c/mL was 29% (PHIVY) and 24% (NPHIVY). For PHIVY and NPHIVY, outpatient visit rates were higher at younger ages (13-17 years and 18-23 years), lower CD4 (< 200 and 200-499/mL), and among those prescribed ARVs. Rates of ED visits and inpatient days were higher during PT spent at older ages (18-23 years and 24-30 years), lower CD4 (< 200 and 200-499/mL), and VL ≥400 c/mL. Utilization was higher among PHIVY than NPHIVY (outpatient: 12.1 vs. 6.0/PY; ED: 0.4 vs. 0.3/PY; inpatient: 1.5 vs. 0.8/PY). Conclusions: More ED visits and inpatient days were observed during time spent at older ages, lower CD4 count, and VL ≥400 c/mL. Interventions to improve virologic suppression and immune response may improve outcomes, and thus decrease costly resource utilization, for AYA with HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Higher Acuity Resource Utilization With Older Age and Poorer HIV Control in Adolescents and Young Adults in the HIV Research Network.
- Author
-
Neilan, Anne M., Lu, Frances, Gebo, Kelly A., Diaz-Reyes, Rebeca, Mingshu Huang, Parker, Robert A., Karalius, Brad, Patel, Kunjal, Voss, Cindy, Ciaranello, Andrea L., and Agwu, Allison L.
- Abstract
Background: Adolescents and young adults (AYA) with HIV experience poorer health outcomes compared with adults. To improve care for AYA with HIV, information about patterns of costly health care resource utilization is needed. Methods: Among 13-30 year olds in the US HIV Research Network, we stratified outpatient visits, emergency department (ED) visits, and inpatient days/person-year (PY) by HIV acquisition model [perinatal (PHIVY) and nonperinatal (NPHIVY)], age (13-17, 18-23, and 24-30 years), CD4 strata (<200, 200-499, and ≥500 cells/µL), and viral load (VL) suppression (<, ≥400 copies/mL [c/mL]) combined with antiretroviral (ARV) use. Results: Among 4540 AYA (PHIVY: 15%; NPHIVY: 85%), mean follow-up was 2.8 years. Among PHIVY, most person-time (PT) was spent between ages 13 and 23 years (13-17 years: 43%; 18-23 years: 45%), CD4 ≥500/µL (61%), and VL <400 c/mL (69%). Among NPHIVY, most PT was spent between ages 24 and 30 years (56%), with CD4 ≥500/mL (54%), and with VL <400 c/mL (67%). PT spent while prescribed ARVs and with VL ≥400 c/mL was 29% (PHIVY) and 24% (NPHIVY). For PHIVY and NPHIVY, outpatient visit rates were higher at younger ages (13-17 years and 18-23 years), lower CD4 (<200 and 200-499/µL), and among those prescribed ARVs. Rates of ED visits and inpatient days were higher during PT spent at older ages (18-23 years and 24-30 years), lower CD4 (<200 and 200-499/µL), and VL ≥400 c/µL. Utilization was higher among PHIVY than NPHIVY (outpatient: 12.1 vs. 6.0/PY; ED: 0.4 vs. 0.3/PY; inpatient: 1.5 vs. 0.8/PY). Conclusions: More ED visits and inpatient days were observed during time spent at older ages, lower CD4 count, and VL ≥400 c/µL. Interventions to improve virologic suppression and immune response may improve outcomes, and thus decrease costly resource utilization, for AYA with HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. HIV infection in older people.
- Author
-
Gebo, Kelly A.
- Subjects
- *
HIV-positive persons , *HIGHLY active antiretroviral therapy , *LENTIVIRUS diseases , *AIDS treatment , *DISEASES in older people , *THERAPEUTICS - Abstract
The author comments on the increasing median age of people living with human immunodeficiency virus (HIV) infection in the developed world due to improved longevity from highly active antiretroviral therapy (HAART) and the increase in new HIV infection cases in older people. She predicts that the prevalence of HIV in older people will continue to increase in the next decade. She notes the higher morbidity, higher mortality, and shorter AIDS free survival of older people compared to younger people during the early days of the HIV epidemic.
- Published
- 2009
- Full Text
- View/download PDF
37. Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us Research Program.
- Author
-
Yeh, Hsueh-Han, Peltz-Rauchman, Cathryn, Johnson, Christine C., Pawloski, Pamala A., Chesla, David, Waring, Stephen C., Stevens, Alan B., Epstein, Mara, Joseph, Christine, Miller-Matero, Lisa R., Gui, Hongsheng, Tang, Amy, Boerwinkle, Eric, Cicek, Mine, Clark, Cheryl R., Cohn, Elizabeth, Gebo, Kelly, Loperena, Roxana, Mayo, Kelsey, and Mockrin, Stephen
- Subjects
- *
OPIOID analgesics , *OPIOID abuse , *NALTREXONE , *OPIOIDS , *ELECTRONIC health records , *ETHNIC groups , *LOGISTIC regression analysis - Abstract
Background: The All of Us Research Program enrolls diverse US participants which provide a unique opportunity to better understand the problem of opioid use. This study aims to estimate the prevalence of opioid use and its association with sociodemographic characteristics from survey data and electronic health record (EHR). Methods: A total of 214,206 participants were included in this study who competed survey modules and shared EHR data. Adjusted logistic regressions were used to explore the associations between sociodemographic characteristics and opioid use. Results: The lifetime prevalence of street opioids was 4%, and the nonmedical use of prescription opioids was 9%. Men had higher odds of lifetime opioid use (aOR: 1.4 to 3.1) but reduced odds of current nonmedical use of prescription opioids (aOR: 0.6). Participants from other racial and ethnic groups were at reduced odds of lifetime use (aOR: 0.2 to 0.9) but increased odds of current use (aOR: 1.9 to 9.9) compared with non-Hispanic White participants. Foreign-born participants were at reduced risks of opioid use and diagnosed with opioid use disorders (OUD) compared with US-born participants (aOR: 0.36 to 0.67). Men, Younger, White, and US-born participants are more likely to have OUD. Conclusions: All of Us research data can be used as an indicator of national trends for monitoring the prevalence of receiving prescription opioids, diagnosis of OUD, and non-medical use of opioids in the US. The program employs a longitudinal design for routinely collecting health-related data including EHR data, that will contribute to the literature by providing important clinical information related to opioids over time. Additionally, this data will enhance the estimates of the prevalence of OUD among diverse populations, including groups that are underrepresented in the national survey data. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine.
- Author
-
Jetsupphasuk, Michael, Hudgens, Michael G, Lu, Haidong, Cole, Stephen R, Edwards, Jessie K, Adimora, Adaora A, Althoff, Keri N, Silverberg, Michael J, Rebeiro, Peter F, Lima, Viviane D, Marconi, Vincent C, Sterling, Timothy R, Horberg, Michael A, Gill, M John, Kitahata, Mari M, Moore, Richard D, Lang, Raynell, Gebo, Kelly, Rabkin, Charles, and Eron, Joseph J
- Subjects
- *
HIV infection complications , *AIDS prevention , *STROKE prevention , *HIV infection prognosis , *HIV infections , *CAUSES of death , *EFAVIRENZ , *DRUG efficacy , *CHRONIC kidney failure , *HIV-positive persons , *HIV integrase inhibitors , *CONFIDENCE intervals , *INDIVIDUALIZED medicine , *MYOCARDIAL infarction , *RISK assessment , *COMPARATIVE studies , *DESCRIPTIVE statistics , *RESEARCH funding , *SOCIODEMOGRAPHIC factors , *LIVER failure - Abstract
In first-line antiretroviral therapy (ART) for human immunodeficiency virus (HIV) treatment, some subgroups of patients may respond better to an efavirenz-based regimen than an integrase strand transfer inhibitor (InSTI)-based regimen, or vice versa, due to patient characteristics modifying treatment effects. Using data based on nearly 16,000 patients from the North American AIDS Cohort Collaboration on Research and Design from 2009–2016, statistical methods for precision medicine were employed to estimate an optimal treatment rule that minimizes the 5-year risk of the composite outcome of acquired immune deficiency syndrome (AIDS)-defining illnesses, serious non-AIDS events, and all-cause mortality. The treatment rules considered were functions that recommend either an efavirenz- or InSTI-based regimen conditional on baseline patient characteristics such as demographic information, laboratory results, and health history. The estimated 5-year risk under the estimated optimal treatment rule was 10.0% (95% confidence interval (CI): 8.6, 11.3), corresponding to an absolute risk reduction of 2.3% (95% CI: 0.9, 3.8) when compared with recommending an efavirenz-based regimen for all patients and 2.6% (95% CI: 1.0, 4.2) when compared with recommending an InSTI-based regimen for all. Tailoring ART to individual patient characteristics may reduce 5-year risk of the composite outcome compared with assigning all patients the same drug regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample.
- Author
-
Bloch, Evan M, Goel, Ruchika, Zhu, Xianming, Patel, Eshan U, Shoham, Shmuel, Sullivan, David J, Gebo, Kelly A, Casadevall, Arturo, and Tobian, Aaron A R
- Subjects
- *
COVID-19 , *COVID-19 treatment , *AGE distribution , *RACE , *POPULATION geography , *SEVERITY of illness index , *HOSPITAL care , *HEALTH insurance , *DESCRIPTIVE statistics , *RESEARCH funding , *SEROTHERAPY , *HEALTH equity , *SECONDARY analysis - Abstract
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) use between October and December 2020 was characterized using the National Inpatient Sample database. CCP was administered in 18.0% of COVID-19-associated hospitalizations and was strongly associated with older age and increased disease severity. There were disparities in the receipt of CCP by race and ethnicity, geography, and insurance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
- Author
-
Lea, Alexandra N, Leyden, Wendy A, Sofrygin, Oleg, Marafino, Ben J, Skarbinski, Jacek, Napravnik, Sonia, Agil, Deana, Augenbraun, Michael, Benning, Lorie, Horberg, Michael A, Jefferson, Celeena, Marconi, Vincent C, Park, Lesley S, Gordon, Kirsha S, Bastarache, Lisa, Gangireddy, Srushti, Althoff, Keri N, Coburn, Sally B, Gebo, Kelly A, and Lang, Raynell
- Subjects
- *
HIV prevention , *HIV infections , *COVID-19 , *CONFIDENCE intervals , *TENOFOVIR , *RNA , *SEVERITY of illness index , *PRE-exposure prophylaxis , *RISK assessment , *ARTIFICIAL respiration , *TREATMENT effectiveness , *HOSPITAL care , *DESCRIPTIVE statistics , *RESEARCH funding , *ODDS ratio , *HIV , *PSYCHOLOGY of HIV-positive persons - Abstract
Background People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir, used by PWH for HIV treatment and people without HIV (PWoH) for HIV prevention, was associated with protection. Methods Within 6 cohorts of PWH and PWoH in the United States, we compared the 90-day risk of any hospitalization, COVID-19 hospitalization, and mechanical ventilation or death by HIV status and by prior exposure to tenofovir, among those with severe acute respiratory syndrome coronavirus 2 infection between 1 March and 30 November 2020. Adjusted risk ratios (aRRs) were estimated by targeted maximum likelihood estimation, with adjustment for demographics, cohort, smoking, body mass index, Charlson comorbidity index, calendar period of first infection, and CD4 cell counts and HIV RNA levels (in PWH only). Results Among PWH (n = 1785), 15% were hospitalized for COVID-19 and 5% received mechanical ventilation or died, compared with 6% and 2%, respectively, for PWoH (n = 189 351). Outcome prevalence was lower for PWH and PWoH with prior tenofovir use. In adjusted analyses, PWH were at increased risk compared with PWoH for any hospitalization (aRR, 1.31 [95% confidence interval, 1.20–1.44]), COVID-19 hospitalizations (1.29 [1.15–1.45]), and mechanical ventilation or death (1.51 [1.19–1.92]). Prior tenofovir use was associated with reduced hospitalizations among PWH (aRR, 0.85 [95% confidence interval,.73–.99]) and PWoH (0.71 [.62–.81]). Conclusions Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Mpox in people with advanced HIV infection: a global case series.
- Author
-
Mitjà, Oriol, Alemany, Andrea, Marks, Michael, Lezama Mora, Jezer I, Rodríguez-Aldama, Juan Carlos, Torres Silva, Mayara Secco, Corral Herrera, Ever Arturo, Crabtree-Ramirez, Brenda, Blanco, José Luis, Girometti, Nicolo, Mazzotta, Valentina, Hazra, Aniruddha, Silva, Macarena, Montenegro-Idrogo, Juan José, Gebo, Kelly, Ghosn, Jade, Peña Vázquez, María Fernanda, Matos Prado, Eduardo, Unigwe, Uche, and Villar-García, Judit
- Subjects
- *
IMMUNE reconstitution inflammatory syndrome , *HIV infections , *MONKEYPOX , *HIV-positive persons , *CD4 lymphocyte count , *VIRAL load - Abstract
People living with HIV have accounted for 38–50% of those affected in the 2022 multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell counts and similar outcomes to those without HIV. Emerging data suggest worse clinical outcomes and higher mortality in people with more advanced HIV. We describe the clinical characteristics and outcomes of mpox in a cohort of people with HIV and low CD4 cell counts (CD4 <350 cells per mm3). A network of clinicians from 19 countries provided data of confirmed mpox cases between May 11, 2022, and Jan 18, 2023, in people with HIV infection. Contributing centres completed deidentified structured case report sheets to include variables of interest relevant to people living with HIV and to capture more severe outcomes. We restricted this series to include only adults older than 18 years living with HIV and with a CD4 cell count of less than 350 cells per mm3 or, in settings where a CD4 count was not always routinely available, an HIV infection clinically classified as US Centers for Disease Control and Prevention stage C. We describe their clinical presentation, complications, and causes of death. Analyses were descriptive. We included data of 382 cases: 367 cisgender men, four cisgender women, and ten transgender women. The median age of individuals included was 35 (IQR 30–43) years. At mpox diagnosis, 349 (91%) individuals were known to be living with HIV; 228 (65%) of 349 adherent to antiretroviral therapy (ART); 32 (8%) of 382 had a concurrent opportunistic illness. The median CD4 cell count was 211 (IQR 117–291) cells per mm3, with 85 (22%) individuals with CD4 cell counts of less than 100 cells per mm3 and 94 (25%) with 100–200 cells per mm3. Overall, 193 (51%) of 382 had undetectable viral load. Severe complications were more common in people with a CD4 cell count of less than 100 cells per mm3 than in those with more than 300 cells per mm3, including necrotising skin lesions (54% vs 7%), lung involvement (29% vs 0%) occasionally with nodules, and secondary infections and sepsis (44% vs 9%). Overall, 107 (28%) of 382 were hospitalised, of whom 27 (25%) died. All deaths occurred in people with CD4 counts of less than 200 cells per mm3. Among people with CD4 counts of less than 200 cells per mm3, more deaths occurred in those with high HIV viral load. An immune reconstitution inflammatory syndrome to mpox was suspected in 21 (25%) of 85 people initiated or re-initiated on ART, of whom 12 (57%) of 21 died. 62 (16%) of 382 received tecovirimat and seven (2%) received cidofovir or brincidofovir. Three individuals had laboratory confirmation of tecovirimat resistance. A severe necrotising form of mpox in the context of advanced immunosuppression appears to behave like an AIDS-defining condition, with a high prevalence of fulminant dermatological and systemic manifestations and death. None. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Telemedicine Use Among People With HIV in 2021: The Hybrid-Care Environment.
- Author
-
El-Nahal, Walid G., Chander, Geetanjali, Jones, Joyce L., Fojo, Anthony T., Keruly, Jeanne C., Manabe, Yukari C., Moore, Richard D., Gebo, Kelly A., and Lesko, Catherine R.
- Abstract
Background: Telemedicine use for the care of people with HIV (PWH) significantly expanded during the COVID-19 pandemic. During 2021, vaccine uptake increased and patients were encouraged to resume in-person care, resulting in a mixture of in-person and telemedicine visits. We studied how different patient populations used telemedicine in this hybrid-care environment. Methods: Using observational data from patients enrolled in the Johns Hopkins HIV Clinical Cohort, we analyzed all in-person and telemedicine HIV primary care visits completed in an HIV clinic from January 1st, 2021, to December 31st, 2021. We used log-binomial regression to investigate the association between patient characteristics and the probability of completing a telemedicine versus in-person visit and the probability of completing a video versus telephone visit. Results: A total of 5518 visits were completed by 1884 patients; 4282 (77.6%) visits were in-person, 800 (14.5%) by phone, and 436 (7.9%) by video. The relative risk (RR) of completing telemedicine vs. in-person visits was 0.65 (95% Confidence Interval (CI): 0.47, 0.91) for patients age 65 years or older vs. age 20–39 years; 0.84 (95% CI: 0.72, 0.98) for male patients vs. female patients; 0.81 (95% CI: 0.66, 0.99) for Black vs. White patients; 0.62 (95% CI: 0.49, 0.79) for patients in the highest vs. lowest quartile of Area Deprivation Index; and 1.52 (95% CI: 1.26, 1.84) for patients >15 miles vs. <5 miles from clinic. Conclusions: In the second year of the pandemic, overall in-person care was used more than telemedicine and significant differences persist across subgroups in telemedicine uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.
- Author
-
Shoham, Shmuel, Bloch, Evan M, Casadevall, Arturo, Hanley, Daniel, Lau, Bryan, Gebo, Kelly, Cachay, Edward, Kassaye, Seble G, Paxton, James H, Gerber, Jonathan, Levine, Adam C, Naeim, Arash, Currier, Judith, Patel, Bela, Allen, Elizabeth S, Anjan, Shweta, Appel, Lawrence, Baksh, Sheriza, Blair, Paul W, and Bowen, Anthony
- Subjects
- *
REVERSE transcriptase polymerase chain reaction , *DRUG efficacy , *COVID-19 treatment , *COVID-19 , *BLOOD transfusion , *TIME , *MEDICAL screening , *TREATMENT effectiveness , *CONVALESCENT plasma , *BLIND experiment , *ENZYME-linked immunosorbent assay , *SEROTHERAPY , *COVID-19 testing , *PATIENT safety , *EVALUATION - Abstract
Background The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection. Methods This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection. Results In total, 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for screening SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) positivity. Of the remaining 168 participants, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25.3 vs 25.2 days; P =.49) and COVID-19 (26.3 vs 25.9 days; P =.35) was similar for both groups. Conclusions Administration of high-titer CCP as post-exposure prophylaxis, although appearing safe, did not prevent SARS-CoV-2 infection. Clinical Trials Registration NCT04323800. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. A Growing Number of Men Who Have Sex With Men Aging With HIV (20212031): A Comparison of Two Microsimulation Models.
- Author
-
Hyle, Emily P, Kasaie, Parastu, Schwamm, Eli, Stewart, Cameron, Humes, Elizabeth, Reddy, Krishna P, Rebeiro, Peter F, Stanic, Tijana, Pei, Pamela P, Gerace, Lucas, Ang, Luke, Gebo, Kelly A, Yu, Liyang, Shebl, Fatma M, Freedberg, Kenneth A, and Althoff, Keri N
- Subjects
- *
OLDER men , *AGE distribution , *HIV , *HEALTH policy , *PRE-exposure prophylaxis - Abstract
Background Men who have sex with men (MSM) on antiretroviral therapy (ART) are at risk for multimorbidity as life expectancy increases. Simulation models can project population sizes and age distributions to assist with health policy planning. Methods We populated the CEPAC-US model with CDC data to project the HIV epidemic among MSM in the United States. The PEARL model was predominantly informed by NA-ACCORD data (20092017). We compared projected population sizes and age distributions of MSM receiving ART (20212031) and investigated how parameters and assumptions affected results. Results We projected an aging and increasing population of MSM on ART: CEPAC-US, mean age 48.6 (SD 13.7) years in 2021 versus 53.9 (SD 15.0) years in 2031; PEARL, 46.7 (SD 13.2) years versus 49.2 (SD 14.6) years. We projected 548 800 MSM on ART (147 020 65 years) in 2031 (CEPAC-US) and 599 410 (113 400 65 years) (PEARL). Compared with PEARL, CEPAC-US projected a smaller population of MSM on ART by 2031 and a slower increase in population size, driven by higher estimates of disengagement in care and mortality. Conclusions Findings from two structurally distinct microsimulation models suggest that the MSM population receiving ART in the United States will increase and age over the next decade. Subgroup-specific data regarding engagement in care and mortality can improve projections and inform health care policy planning. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.
- Author
-
Zalla, Lauren C., Cole, Stephen R., Eron, Joseph J., Adimora, Adaora A., Vines, Anissa I., Althoff, Keri N., Silverberg, Michael J., Horberg, Michael A., Marconi, Vincent C., Coburn, Sally B., Lang, Raynell, Williams, Emily C., Gill, M. John, Gebo, Kelly A., Klein, Marina, Sterling, Timothy R., Rebeiro, Peter F., Mayor, Angel M., Moore, Richard D., and Edwards, Jessie K.
- Subjects
- *
RACE , *HIV-positive persons , *ANTIRETROVIRAL agents , *ETHNICITY , *INTEGRASE inhibitors , *BLACK people - Abstract
Key Points: Questions: Did antiretroviral therapy (ART) prescriptions differ by race and ethnicity among people entering HIV care in the US from 2007-2019? Findings: In this retrospective observational study that included 42 841 individuals entering HIV care, the 1-month probability of ART prescription was not significantly different across most race and ethnicity comparisons. However, Black and Hispanic individuals were significantly less likely than White individuals to receive prescriptions for integrase strand transfer inhibitor (INSTI)–containing ART in earlier time periods but not in later time periods once INSTIs became guideline-recommended therapy. Meaning: Among people entering HIV care within a large research consortium in the US from 2007-2019, there were differences in prescription of INSTI-containing ART by race and ethnicity in earlier time periods but not in later periods, when INSTIs were the guideline-recommended initial treatment for HIV. Importance: Integrase strand transfer inhibitor (INSTI)–containing antiretroviral therapy (ART) is currently the guideline-recommended first-line treatment for HIV. Delayed prescription of INSTI-containing ART may amplify differences and inequities in health outcomes. Objectives: To estimate racial and ethnic differences in the prescription of INSTI-containing ART among adults newly entering HIV care in the US and to examine variation in these differences over time in relation to changes in treatment guidelines. Design, Setting, and Participants: Retrospective observational study of 42 841 adults entering HIV care from October 12, 2007, when the first INSTI was approved by the US Food and Drug Administration, to April 30, 2019, at more than 200 clinical sites contributing to the North American AIDS Cohort Collaboration on Research and Design. Exposures: Combined race and ethnicity as reported in patient medical records. Main Outcomes and Measures: Probability of initial prescription of ART within 1 month of care entry and probability of being prescribed INSTI-containing ART. Differences among non-Hispanic Black and Hispanic patients compared with non-Hispanic White patients were estimated by calendar year and time period in relation to changes in national guidelines on the timing of treatment initiation and recommended initial treatment regimens. Results: Of 41 263 patients with information on race and ethnicity, 19 378 (47%) as non-Hispanic Black, 6798 (16%) identified as Hispanic, and 13 539 (33%) as non-Hispanic White; 36 394 patients (85%) were male, and the median age was 42 years (IQR, 30 to 51). From 2007-2015, when guidelines recommended treatment initiation based on CD4+ cell count, the probability of ART initiation within 1 month of care entry was 45% among White patients, 45% among Black patients (difference, 0% [95% CI, −1% to 1%]), and 51% among Hispanic patients (difference, 5% [95% CI, 4% to 7%]). From 2016-2019, when guidelines strongly recommended treating all patients regardless of CD4+ cell count, this probability increased to 66% among White patients, 68% among Black patients (difference, 2% [95% CI, −1% to 5%]), and 71% among Hispanic patients (difference, 5% [95% CI, 1% to 9%]). INSTIs were prescribed to 22% of White patients and only 17% of Black patients (difference, −5% [95% CI, −7% to −4%]) and 17% of Hispanic patients (difference, −5% [95% CI, −7% to −3%]) from 2009-2014, when INSTIs were approved as initial therapy but were not yet guideline recommended. Significant differences persisted for Black patients (difference, −6% [95% CI, −8% to −4%]) but not for Hispanic patients (difference, −1% [95% CI, −4% to 2%]) compared with White patients from 2014-2017, when INSTI-containing ART was a guideline-recommended option for initial therapy; differences by race and ethnicity were not statistically significant from 2017-2019, when INSTI-containing ART was the single recommended initial therapy for most people with HIV. Conclusions and Relevance: Among adults entering HIV care within a large US research consortium from 2007-2019, the 1-month probability of ART prescription was not significantly different across most races and ethnicities, although Black and Hispanic patients were significantly less likely than White patients to receive INSTI-containing ART in earlier time periods but not after INSTIs became guideline-recommended initial therapy for most people with HIV. Additional research is needed to understand the underlying racial and ethnic differences and whether the differences in prescribing were associated with clinical outcomes. This retrospective observational study of adults entering HIV care between 2007 and 2019 compares differences in the prescription of integrase inhibitor–containing antiretroviral therapy by patient race and ethnicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Absence of pathogenic viruses in COVID‐19 convalescent plasma.
- Author
-
Kandathil, Abraham J., Benner, Sarah E., Bloch, Evan M., Shrestha, Ruchee, Ajayi, Olivia, Zhu, Xianming, Caturegli, Patrizio P., Shoham, Shmuel, Sullivan, David, Gebo, Kelly, Quinn, Thomas C., Casadevall, Arturo, Hanley, Daniel, Pekosz, Andrew, Redd, Andrew D., Balagopal, Ashwin, and Tobian, Aaron A. R.
- Subjects
- *
CONVALESCENT plasma , *PATHOGENIC viruses , *TORQUE teno virus , *DNA primers , *COVID-19 - Abstract
Background: It is important to maintain the safety of blood products by avoiding the transfusion of units with known and novel viral pathogens. It is unknown whether COVID‐19 convalescent plasma (CCP) may contain pathogenic viruses (either newly acquired or reactivated) that are not routinely screened for by blood centers. Methods: The DNA virome was characterized in potential CCP donors (n = 30) using viral genome specific PCR primers to identify DNA plasma virome members of the Herpesviridae [Epstein Barr Virus (EBV), cytomegalovirus (CMV), human herpesvirus 6A/B, human herpesvirus 7] and Anelloviridae [Torque teno viruses (TTV), Torque teno mini viruses (TTMV), and Torque teno midi viruses (TTMDV)] families. In addition, the RNA plasma virome was characterized using unbiased metagenomic sequencing. Sequencing was done on a HiSeq2500 using high output mode with a read length of 2X100 bp. The sequencing reads were taxonomically classified using Kraken2. CMV and EBV seroprevalence were evaluated using a chemiluminescent immunoassay. Results: TTV and TTMDV were detected in 12 (40%) and 4 (13%) of the 30 study participants, respectively; TTMDV was always associated with infection with TTV. We did not observe TTMV DNAemia. Despite CMV and EBV seroprevalences of 33.3% and 93.3%, respectively, we did not detect Herpesviridae DNA among the study participants. Metagenomic sequencing did not reveal any human RNA viruses in CCP, including no evidence of circulating SARS‐CoV‐2. Discussion: There was no evidence of pathogenic viruses, whether newly acquired or reactivated, in CCP despite the presence of non‐pathogenic Anelloviridae. These results confirm the growing safety data supporting CCP. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Achieving a Representative Sample of Asian Americans in Biomedical Research Through Community-Based Approaches: Comparing Demographic Data in the All of Us Research Program With the American Community Survey.
- Author
-
Randal, Fornessa T., Lozano, Paula, Qi, Siya, Maene, Chieko, Shah, Sameep, Mo, Yicklun, Ratsimbazafy, Francis, Boerwinkle, Eric, Cicek, Mine, Clark, Cheryl R., Cohn, Elizabeth, Gebo, Kelly, Loperena, Roxana, Mayo, Kelsey, Mockrin, Stephen, Ohno-Machado, Lucila, Schully, Sheri, Ramirez, Andrea H., Aschebrook-Kilfoy, Briseis, and Ahsan, Habibul
- Subjects
- *
HUMAN research subjects , *PATIENT selection , *ASIANS , *PSYCHOSOCIAL factors , *DESCRIPTIVE statistics , *RESEARCH funding , *RESEARCH bias , *HEALTH equity , *MEDICAL research - Abstract
Background: Underrepresented persons are often not included in biomedical research. It is unknown if the general Asian American population is being represented in All of Us. The purpose of this study was to compare the Asian demographic data in the All of Us cohort with the Asian nationally representative data from the American Community Survey. Method: Demographic characteristics and health literacy of Asians in All of Us were examined. Findings were qualitatively compared with the Asian data in the 2019 American Community Survey 1-year estimate. Results: Compared with the national composition of Asians, less All of Us participants were born outside the United States (64% vs 79%), were younger, and had higher levels of education (76% vs 52%). Over 60% of All of Us participants reported high levels of health literacy. Conclusion: This study had implications for the development of strategies that ensure diverse populations are represented in biomedical research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation.
- Author
-
Coburn, Sally B., Lang, Raynell, Zhang, Jinbing, Palella, Frank Joseph, Horberg, Michael A., Castillo-Mancilla, Jose, Gebo, Kelly, Galaviz, Karla I., Gill, M. John, Silverberg, Michael J., Hulgan, Todd, Elion, Richard A., Justice, Amy C., Moore, Richard D., and Althoff, Keri N.
- Abstract
Background: We characterized trends in statin eligibility and subsequent statin initiation among people with HIV (PWH) from 2001 to 2017 and identified predictors of statin initiation between 2014 and 2017. Setting: PWH participating in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) enrolled in 12 US cohorts collecting data on statin eligibility criteria/prescriptions from 2001 to 2017. Methods: We determined the annual proportion eligible for statins, initiating statins, and median waiting time (from statin eligibility to initiation). Eligibility was defined using ATP III guidelines (2001–2013) and ACC/AHA guidelines (2014–2017). We assessed initiation predictors in 2014–2017 among statin-eligible PWH using Poisson regression, estimating adjusted prevalence ratios (aPRs) with 95% confidence intervals (95% CIs). Results: Among 16,409 PWH, 7386 (45%) met statin eligibility criteria per guidelines (2001–2017). From 2001 to 2013, statin eligibility ranged from 22% to 25%. Initiation increased from 13% to 45%. In 2014, 51% were statin-eligible, among whom 25% initiated statins, which increased to 32% by 2017. Median waiting time to initiation among those we observed declined over time. Per 10-year increase in age, initiation increased 46% (aPR 1.46, 95% CI: 1.29 to 1.67). Per 1-year increase in calendar year from 2014 to 2017, there was a 41% increase in the likelihood of statin initiation (aPR 1.41, 95% CI: 1.25 to 1.58). Conclusions: There is a substantial statin treatment gap, amplified by the 2013 ACC/AHA guidelines. Measures are warranted to clarify reasons we observe this gap, and if necessary, increase statin use consistent with guidelines including efforts to help providers identify appropriate candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. An Overview of Cancer in the First 315,000 All of Us Participants.
- Author
-
Aschebrook-Kilfoy, Briseis, Zakin, Paul, Craver, Andrew, Shah, Sameep, Kibriya, Muhammad G., Stepniak, Elizabeth, Ramirez, Andrea, Clark, Cheryl, Cohn, Elizabeth, Ohno-Machado, Lucila, Cicek, Mine, Boerwinkle, Eric, Schully, Sheri D., Mockrin, Stephen, Gebo, Kelly, Mayo, Kelsey, Ratsimbazafy, Francis, Sanders, Alan, Shah, Raj C., and Argos, Maria
- Subjects
- *
ETHNICITY , *ELECTRONIC health records , *RACE , *EARLY detection of cancer , *CANCER research - Abstract
Introduction: The NIH All of Us Research Program will have the scale and scope to enable research for a wide range of diseases, including cancer. The program's focus on diversity and inclusion promises a better understanding of the unequal burden of cancer. Preliminary cancer ascertainment in the All of Us cohort from two data sources (self-reported versus electronic health records (EHR)) is considered. Materials and methods: This work was performed on data collected from the All of Us Research Program's 315,297 enrolled participants to date using the Researcher Workbench, where approved researchers can access and analyze All of Us data on cancer and other diseases. Cancer case ascertainment was performed using data from EHR and self-reported surveys across key factors. Distribution of cancer types and concordance of data sources by cancer site and demographics is analyzed. Results and discussion: Data collected from 315,297 participants resulted in 13,298 cancer cases detected in the survey (in 89,261 participants), 23,520 cancer cases detected in the EHR (in 203,813 participants), and 7,123 cancer cases detected across both sources (in 62,497 participants). Key differences in survey completion by race/ethnicity impacted the makeup of cohorts when compared to cancer in the EHR and national NCI SEER data. Conclusions: This study provides key insight into cancer detection in the All of Us Research Program and points to the existing strengths and limitations of All of Us as a platform for cancer research now and in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Time Between Viral Loads for People With HIV During the COVID-19 Pandemic.
- Author
-
El-Nahal, Walid G., Shen, Nicola M., Keruly, Jeanne C., Jones, Joyce L., Fojo, Anthony T., Manabe, Yukari C., Moore, Richard D., Gebo, Kelly A., Chander, Geetanjali, and Lesko, Catherine R.
- Abstract
Supplemental Digital Content is Available in the Text. Background: During the COVID-19 pandemic, patients experienced significant care disruptions, including laboratory monitoring. We investigated changes in the time between viral load (VL) checks for people with HIV (PWH) associated with the pandemic. Setting and Methods: This was an observational analysis of VLs of PWH in routine care at a large subspecialty clinic. At pandemic onset, the clinic temporarily closed its onsite laboratory. The exposure was time period (time varying): prepandemic (January 1, 2019–March 15, 2020); pandemic laboratory closed (March 16–July 12, 2020); and pandemic laboratory open (July 13–December 31, 2020). We estimated time from an index VL to a subsequent VL, stratified by whether the index VL was suppressed (≤200 copies/mL). We also calculated cumulative incidence of a nonsuppressed VL following a suppressed index VL, and of resuppression following a loss of viral suppression. Results: Compared with prepandemic, hazard ratios for next VL check were 0.34 (95% CI: 0.30 to 0.37, laboratory-closed) and 0.73 (CI: 0.68 to 0.78, laboratory-open) for suppressed patients, and 0.56 (CI: 0.42 to 0.79, laboratory-closed) and 0.92 (95% CI: 0.76 to 1.10, laboratory-open) for nonsuppressed patients. The 12-month cumulative incidence of loss of suppression was the same in the pandemic laboratory-open (4%) and prepandemic (4%) period. The hazard of resuppression following the loss of suppression was lower during the pandemic laboratory-open versus the prepandemic period (hazard ratio: 0.68, 95% CI: 0.50 to 0.92). Conclusions: Early pandemic restrictions and laboratory closure significantly delayed VL monitoring. Once the laboratory reopened, nonsuppressed patients resumed normal monitoring. Suppressed patients still had a delay but no significant loss of suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.